Regenerative Health Clinic Compliance: The 5 Things That Actually Shut Clinics Down

What Federal and State Regulators Enforce Against, and How Legitimate Clinics Stay on the Right Side of It

Most Clinics That Fail Do Not Fail Clinically

Ask an entrepreneur what could go wrong opening a regenerative health clinic and most will describe a business problem — not enough patients, a bad location, a partner who walks. Those happen. But the clinics that close abruptly, that lose their ability to operate in a matter of weeks rather than declining over quarters, almost never fail for those reasons.

They fail because of a structural decision made early, usually without understanding it was a decision at all. A sourcing relationship accepted on a vendor's word. A marketing claim copied from a competitor's website. An ownership arrangement drafted from a generic template. None of those feel like risks at the time. All of them are.

This guide covers the five that actually produce enforcement. It is written for people evaluating or operating a clinic, not for lawyers, and it is written plainly because the alternative — vague warnings about consulting professionals — is how people end up learning these rules the expensive way.

This post is educational and does not constitute legal advice. Regulatory requirements vary by state and change over time. Clinic owners should work with healthcare counsel admitted in their state before making structural, sourcing, or marketing decisions.

1. Owning the Clinical Practice When You Are Not Licensed to

Most states restrict the practice of medicine to licensed individuals, and extend that restriction to business entities. The doctrine is generally called the corporate practice of medicine. Its practical effect is that a non-physician cannot simply form a company, hire a doctor, and direct patient care.

What is permitted in most states is a structure that separates the business from the clinical practice. The entrepreneur owns a management services organization providing everything non-clinical — facility, staffing, technology, marketing, administration. A licensed clinician owns the professional entity that holds the clinical license and makes every patient care decision. A management services agreement connects them, with the management fee set at fair market value.

This is the standard model, not a workaround. What draws scrutiny is not the structure itself but structures that exist only on paper — where the business owner is functionally directing clinical decisions regardless of what the agreement says, or where the management fee is arranged so that it varies with the volume or value of clinical services in a way that resembles fee-splitting.

The ownership question is the one prospective clinic owners ask first, and it deserves more than a paragraph. Can a Non-Physician Own a TRT or Hormone Clinic covers the structure in full, including the state-by-state variation in who can hold prescribing authority.

2. Offering Products the FDA Has Not Approved

This is the single largest source of enforcement action in the regenerative health space, and the category where the gap between what is marketed and what is lawful is widest.

The clearest example is exosomes. The FDA's position is not ambiguous and has been public since 2019: there are currently no FDA-approved exosome products. Exosomes used to treat diseases or conditions in humans are regulated as drugs and biological products, subject to premarket review and approval. The agency issued that notification following multiple reports of serious adverse events in patients treated with unapproved exosome products.

Clinics offering them are not operating in a grey area. They are marketing unapproved biologics, and the FDA has said so repeatedly in warning letters. ACG does not help clients build a business around exosome therapy, for exactly this reason.

Stem cell products sit differently. Certain same-day autologous procedures qualify for an exception under 21 CFR 1271.15(b) when tissue is removed from and implanted into the same individual during the same surgical procedure, with processing limited to rinsing, cleansing, sizing, or shaping. Donor-derived products do not qualify for that exception under any circumstances.

The exosome question specifically is covered in Exosomes and the FDA: What Every Clinic Owner Needs to Know, and the stem cell framework in the ACG stem cell pillar.

3. Sourcing Compounded Medications Outside the Legal Framework

Compounded medications are legitimate and widely used in this space. What makes them lawful is the framework they are prepared under. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act define it: 503A covers compounding by a licensed pharmacist in a state-licensed pharmacy for an identified individual patient on receipt of a valid prescription, while 503B covers outsourcing facilities registered with the FDA and subject to current good manufacturing practice requirements.

Peptide therapies, hormone preparations, and similar products are defensible when they are prescriber-directed and sourced through licensed 503A or 503B pharmacies. They are not defensible when sourced from vendors selling material labeled for research use only, or when treated as products a clinic stocks and sells rather than medications prescribed for a specific patient.

Two additional points that trip up new operators. A product being available from a supplier says nothing about whether a clinic may lawfully offer it — the supplier's compliance and the clinic's compliance are separate questions. And a compounded product cannot be essentially a copy of a commercially available drug, which is why the compounded GLP-1 landscape changed materially once those shortages resolved.

4. Making Claims That Turn a Service Into an Unapproved Drug

This is the failure mode operators least expect, because it does not involve changing anything about the treatment itself. It involves what the clinic says about it.

Under federal law, a product's intended use is established substantially by how it is marketed. A preparation described as supporting general wellness occupies one regulatory position. The same preparation marketed as treating, preventing, or curing a named disease has been converted into a drug claim, and now requires the approval that drugs require.

The FDA has applied this reasoning directly. In enforcement correspondence with exosome manufacturers, the agency has rejected the argument that a product is cosmetic when the company continued marketing it to treat conditions such as skin damage — the marketing established the intended use regardless of how the company characterized the product.

The FTC governs the other half of this. Its Health Products Compliance Guidance sets the standard for substantiation, testimonials, and outcome claims in health advertising. Claims a clinic cannot substantiate at the time they are made are deceptive regardless of whether any patient complains.

The practical discipline is narrower than most clinic marketing assumes. Describe what the service is, who it is appropriate for, and what the clinical process involves. Do not promise outcomes. Do not name diseases the service treats unless the product carries that approved indication. Patient testimonials require the same substantiation as the clinic's own claims.

5. Losing the Ability to Advertise

This one is not a regulator. It is a platform, and for an advertising-dependent clinic the practical consequence can be more immediate than a warning letter.

Advertising platforms enforce their own healthcare rules independently of federal law. Google's healthcare and medicines policy restricts certain healthcare content entirely, requires certification for other categories, and limits personalized advertising for health topics — meaning remarketing and audience targeting that work in other industries are unavailable here.

A clinic that builds its entire patient acquisition on paid advertising, with creative that sits close to the policy line, is one enforcement sweep away from zero new patients. The clinics that survive platform changes are the ones that built organic search presence, referral relationships, and community authority alongside paid acquisition rather than instead of it.

The specific policy traps and what compliant creative looks like are covered in Why Regenerative Clinics Get Their Ad Accounts Banned.

What Enforcement Actually Looks Like

Enforcement in this space is rarely a raid. It usually begins with correspondence — an untitled letter or a warning letter identifying specific violations and requesting a response within a defined window. What happens next depends substantially on how the clinic responds.

Warning letters are public. They are indexed, searchable, and frequently the first result for the clinic's name afterward. The reputational consequence often exceeds the regulatory one.

What the process involves, what a response requires, and what to do if one arrives is covered in What Happens When a Clinic Gets an FDA Warning Letter.

Who You Take Advice From Is a Compliance Decision

There is a sixth risk that does not appear on any regulator's list, and it is worth naming because it underlies the other five: taking structural advice from someone selling you something.

A supplier telling you a product is fine to offer has an interest in your order. A consultant promising specific income has an interest in your engagement — and is also making a claim regulators scrutinize.

Why legitimate consultants will not guarantee income, and what that tells you about the ones who do, is covered in Earnings Claims and the FTC.

How ACG Approaches This

ACG helps clients build clinics that operate within a defensible framework. That includes the entity structure, prescribing arrangements, supplier relationships, clinical documentation, and marketing review that make a clinic durable rather than merely open.

It also includes declining to help with things that cannot be done compliantly. ACG does not help clients build a business around exosome therapy. That is not a limitation of the engagement — it is the point of it.

To discuss the compliance framework for your specific market and clinic type, visit altosconsultinggroup.com/survey.

Frequently Asked Questions

Can a clinic be shut down for something a supplier did?

A clinic's exposure is determined by its own sourcing, marketing, and clinical practices. A supplier's compliance problem does not automatically create one for the clinic, but a clinic that continued offering a product after its supplier received an FDA warning letter is in a materially different position than one that did not. Verifying a supplier's licensing and regulatory standing is the clinic's responsibility, not the supplier's.

Do these rules apply differently to cash-pay clinics?

Not meaningfully. Cash-pay status removes payer and billing exposure, but FDA authority over drugs and biologics, FTC authority over advertising claims, state medical board authority over practice, and platform advertising policies all apply regardless of how the clinic is paid.

What is the single most common compliance mistake?

Assuming that widespread industry practice indicates legality. A service being offered by many clinics in a market says nothing about whether it is lawful. Exosome therapy is the clearest current example — heavily marketed, widely offered, and explicitly identified by the FDA as an unapproved product category.

How often should a clinic review its compliance posture?

At least annually, and immediately after any regulatory development affecting its service categories. This area has changed substantially in recent years — compounded GLP-1 access, peptide classifications, and hormone therapy labeling have all shifted. A compliance review from two years ago is unlikely to reflect current requirements.

Written by Nova, Senior Content Strategist at Altos Consulting Group.